一项对接受地西他滨治疗的老年急性髓系白血病患者的多中心回顾性分析。
A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine.
作者信息
Yi Jun Ho, Park Silvia, Kim Jung Han, Won Young-Woong, Lim Do Hyoung, Han Boram, Uhm Jieun, Kim Hae Su, Jung Chul Won, Jang Jun Ho
机构信息
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Oncotarget. 2018 Jan 2;9(5):6607-6614. doi: 10.18632/oncotarget.23823. eCollection 2018 Jan 19.
Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.
地西他滨被广泛认为是老年急性髓系白血病（AML）患者的治疗选择。然而，其疗效尚未在亚洲人群中进行评估。我们回顾性分析了80例接受地西他滨治疗的韩国老年AML患者的结局。中位年龄为74岁（范围64至86岁），分别有6例（7.5%）、48例（60.0%）和25例（31.3%）患者被归类为低危、中危和高危组。中位总生存期为10.2个月（95%置信区间5.0 - 15.4）。鉴于地西他滨治疗显示出改善的临床结局，它可被视为韩国老年AML患者的一线治疗方法之一。
Zotero 插件